Product Description
Mivacurium chloride (Mivacron) is a new benzylisoquinolinium choline-like diester neuromuscular blocking drug with an onset of action at equipotent doses that is comparable to atracurium and vecuronium but slower than succinylcholine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/1373287/)
Mechanisms of Action: nAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Belgium | Brazil | Canada | Chile | Czech | Denmark | Finland | France | Germany | Hong Kong | Hungary | Ireland | Italy | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Singapore | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|